List view / Grid view
The proposed collaboration between Lonza and Vertex Pharmaceuticals will support…
The proposed collaboration between Lonza and Vertex Pharmaceuticals will support manufacture of stem cell-derived, fully differentiated insulin-producing islet diabetes cell therapies.
Children with cystic fibrosis aged six to11 years could benefit…
Children with cystic fibrosis aged six to11 years could benefit from Kaftrio® in combination with ivacaftor, as a treatment targeting the underlying cause of the disease.
The European Commission has approved the label extension for KALYDECO®…
The European Commission has approved the label extension for KALYDECO® (ivacaftor) to include the treatment of infants with cystic fibrosis between six and 12 months old.
